Insulin Clearance in Health and Disease
Year: 2022
Type: review
Abstract: Insulin action is impaired in type 2 diabetes. The functions of the hormone are an integrated product of insulin secretion from pancreatic β-cells and insulin clearance by receptor-mediated endocytosis and degradation, mostly in liver (hepatocytes) and, to a lower extent, in extrahepatic peripheral tissues. Substantial evidence indicates that genetic or acquired abnormalities of insulin secretion or action predispose to type 2 diabetes. In recent years, along with the discovery of the molecular foundation of receptor-mediated insulin clearance, such as through the membrane glycoprotein CEACAM1, a consensus has begun to emerge that reduction of insulin clearance contributes to the disease process. In this review, we consider the evidence suggesting a pathogenic role for reduced insulin clearance in insulin resistance, obesity, hepatic steatosis, and type 2 diabetes.
Source: Annual Review of Physiology
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: Metabolic Markers and Predictors of Childhood Obesity, CEACAM and Insulin Action, Linking fat metabolism to hepatic fibrosis, Yale University Clinical and Translational Science Award Program, Pathophysiology of Metabolic Defects of Juvenile Obesity, Pathogenesis of youth onset pre-diabetes and Type 2 diabetes, Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
OpenAlex ID: W4306841886
